Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ<sub>A</sub>(N<sub>2</sub>) non-small cell lung cancer

刘翼; 阿迪力; 陆艳荣; 张国庆; 庞作良

doi:10.3969/j.issn.1007-3969.2013.06.009

您当前的位置：

首页 >

文章列表页 >

Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ_A(N₂) non-small cell lung cancer

更新时间：2025-12-31

- Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ_A(N₂) non-small cell lung cancer
- China Oncology Vol. 23, Issue 6, Pages: 452-456(2013)
- 作者机构：
  
  新疆医科大学附属肿瘤医院胸外科,新疆,乌鲁木齐
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.06.009
  CLC：
- Published Online：13 November 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
刘翼,阿迪力,陆艳荣,张国庆,庞作良. Ⅲ

刘翼, 阿迪力, 陆艳荣, et al. Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ_A(N₂) non-small cell lung cancer[J]. China Oncology, 2013, 23(6): 452-456.
刘翼,阿迪力,陆艳荣,张国庆,庞作良. Ⅲ DOI： 10.3969/j.issn.1007-3969.2013.06.009.

刘翼, 阿迪力, 陆艳荣, et al. Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ_A(N₂) non-small cell lung cancer[J]. China Oncology, 2013, 23(6): 452-456. DOI： 10.3969/j.issn.1007-3969.2013.06.009.

摘要

背景与目的：术后放射治疗(postoperative radiotherapy，PORT)在完全性切除的Ⅲ

)期非小细胞肺癌(non-small cell lung cancer，NSCLC)治疗中的临床价值存在争议。本研究分析PORT在完全性切除的Ⅲ

)期NSCLC的疗效。方法：回顾性分析2002年1月—2007年1月126例在我院接受手术治疗的Ⅲ

)期NSCLC患者的临床资料。根据是否行术后放疗分为术后化疗组(n=56)和术后放化疗组(n=70)，分析Ⅲ

)期NSCLC生存期的影响因素。统计分析采用Kaplan-Meier法计算生存率，采用Log-rank比较各组生存的差异。结果：全组患者中位生存期25.0个月，1、3、5年生存率分别为84.4%、32.5%、16.4%。术后化疗组1、3、5年生存率分别为81.2%、28.5%、13.5%，中位生存期为22.4个月，术后化疗联合放疗组1、3、5年生存率分别为88.5%、39.9%、20.0%，中位生存期32.8个月，差异有统计学意义(P=0.033)。术后化疗组出现局部复发的中位时间为9.6个月，术后化疗联合放疗组出现局部复发的中位时间为17.0个月，差异有统计学意义(P=0.001)。单因素分析发现，多站淋巴结转移(P=0.001)、PORT(P=0.033)影响Ⅲ

)期NSCLC的生存率。结论：术后辅助放疗可提高pN2期NSCLC的生存率和降低局部复发。

Abstract

Background and purpose: Postoperative radiotherapy (PORT) in completely resectable stage Ⅲ

) non-small cell lung cancer (NSCLC) is still controversial. The purpose of this study was to analyze the efficiency of PORT in completely resectable stage Ⅲ

) NSCLC. Methods: The clinical data of 126 patients with stage Ⅲ

) NSCLC who was treated with radical surgery f

rom Jan. 2002 to Jan. 2007 were retrospctively analyzed. There were 126 patients for analysis; 70 patients received the postoperative chemotherapy alone (non-PORT)

56 patients received postoperative chemotherapy with radiotherapy. The 126 patients were analyzed the influencing factors of the overall survival (OS). Kaplan-Meier method was used to calculate the OS

and Log-rank was used to compare the difference of OS between the two groups. Results: The median survival time was 25.0 months in all the groups of patients. The 1-

5-year survival rates were 84.4%

32.5%

16.4%. The 1-

and 5-year survival rates were 81.2%

28.5%

13.5% in non-PORT group

and 88.5%

39.9%

20.0% in PORT group. The median survival time was 22.4 months and 32.8 months

the difference was statistically significant (P=0.033). The median time of stage Ⅲ

) NSCLC with locoregional recurrence was 9.6 months in non-PORT group and 17.0 months in PORT group

the difference was statistically significant (P=0.001). Univariate analysis showed that the number of lymph node metastasis station (P=0.001) and PORT (P=0.033) correlated with OS. Conclusion: PORT could improve the survival rate and reduce the locoregional recurrence of stage Ⅲ

) NSCLC.

关键词

Keywords

references

Views

4110

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Related Author

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Yicong LIN

Yue WANG

Related Institution

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Peking University International Hospital

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰

Analyze the curative effect of adjuwant radiotherapy in stage ⅢA(N2) non-small cell lung cancer

DOI：10.3969/j.issn.1007-3969.2013.06.009

摘要

Abstract

关键词

Keywords

references

Analyze the curative effect of adjuwant radiotherapy in stage Ⅲ_A(N₂) non-small cell lung cancer